Effect of serotonin axon injury on the somatostatinergic system in rat frontoparietal cortex

In order to investigate the possibility that, in the rat, some cerebral cortex\ud somatostatin (SS) receptors may be localized presynaptically on the terminals of\ud serotonergic neurons, serotonin [5-hydroxytryptamine, (5-HT)] neurons in the\ud central nervous system were damaged with a local intracerebral injection of the\ud serotonergic neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT). The injection of 5,7-\ud DHT (11 /~g free base dissolved in 10 t~l of isotonic saline containing 0.01%\ud ascorbic acid) in rats produced an reduction by about 74 % in frontoparietal cortical\ud 5-HT content at 1 and 3 weeks after injection. These changes were associated with\ud a significant decrease by about 30 % in the total number of specific SS receptors\ud in the frontoparietal cortex at both times studied without influencing the apparent\ud affinity of the receptors. Together, these results suggest that a portion of the\ud frontoparietal cortex SS receptors may be localized presynaptically on the\ud serotonergic nerve terminals. The 5,7-DHT did not affect SS-like immunoreactivity\ud (SSLI) levels suggesting that SS and 5-HT are not colocalized within the same\ud neuronal elements in the rat frontoparietal cortex

INDICADORES DEMOGRÁFICOS, DE MERCADO LABORAL E INFRAESTRUCTURAS. LÍNEAS DE DESARROLLO.

São apresentados indicadores desenvolvidos no âmbito do projeto OTALEX C, relativos à Sustentabilidade Territorial, mais concretamente com a acessibilidade espacial, designadamente indicadores de acesso em tempos mínimos a serviços básicos sanitários (centros de saúde, hospitais, residências de idosos e centros de dia) e educativos (escolas, estabelecimentos de ensino secundário e superior), bem como a núcleos de população de hierarquia superior (cidades com mais de 20000, 50000 e 200000 habitantes). Estes indicadores serão incorporados à bateria de indicadores de sustentabilidade do projeto OTALEX C

La inteligencia emocional en estudiantes universitarios: diferencias entre el grado de maestro en educación primaria y los grados en ciencias

The interest of this work focuses on the great importance of emotional intelligence has gained in recent years and as, according to Goleman (1996), the union of reason and emotion is fundamental to understanding the development of human intelligence. In addition, several studies show the importance of developing emotional competence in the educational context, and particularly in university students. Through the use of a quantitative method, and more particularly of a cross-sectional design, the objective our study was to evaluate the level of emotional intelligence (attention, clarity and emotional repair) in a sample of 358 students of the Grade of Elementary Master and  Science Grades of the University of Extremadura using the test of self-TMMS 24 Fernández-Berrocal, Extremera and Ramos (2004). The results confirm that there were significant differences in emotional reparation level by sex, and in every one of the dimensions that make up emotional intelligence by the extent to which they are enrolled college students.El interés que nos ha llevado a realizar este trabajo se centra en la gran importancia que ha cobrado la inteligencia emocional en los últimos años y como, según indica Goleman (1996), la unión de la razón y la emoción es fundamental para comprender el desarrollo de la inteligencia humana. Además, diversos estudios muestran la importancia de desarrollar competencias emocionales en el contexto educativo, y más concretamente en los estudiantes universitarios. Mediante una metodología cuantitativa, y más concretamente a partir de un diseño transversal, en nuestro trabajo se pretende evaluar el nivel de inteligencia emocional (atención, claridad y reparación emocional) en una muestra constituida por 358 estudiantes del Grado de Maestro en Educación y Grados en Ciencias de la Universidad de Extremadura mediante el test de autoinforme TMMS-24 de Fernández-Berrocal, Extremera y Ramos (2004). Los resultados obtenidos permitieron afirmar que existen diferencias estadísticamente significativas en el nivel reparación emocional según el sexo, y en todas y cada una de las dimensiones que conforman la inteligencia emocional según el grado en  el que se encuentran matriculados los estudiantes universitarios

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay. Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine's registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference > 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100. Results: A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays. Conclusions: In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay. Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine’s registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference > 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100. Results: A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays. Conclusions: In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed